Management of axilla after neo-adjuvant treatment

Bookmark and Share
Published: 16 Feb 2021
Views: 662
Prof Monica Morrow - Memorial Sloan Kettering Cancer Center, New York, USA

Prof Monica Morrow speaks to ecancer in an online interview for the virtual BGICC 2021 meeting about the use of neo-adjuvant chemotherapy to downstage the axilla of women with breast cancer.

She explains that oncology has reached a time where axillary dissection can no longer ben considered the standard of care for the majority of women with breast cancer and discusses recent trials into alternatives.

Prof Morrow concludes that management of the axilla has become increasingly complex and requires a multi-disciplinary approach.